Geriatric fragility fractures are associated with a human skeletal stem cell defect

Fragility fractures have a limited capacity to regenerate, and impaired fracture healing is a leading cause of morbidity in the elderly. The recent identification of a highly purified bona fide human skeletal stem cell (hSSC) and its committed downstream progenitor cell populations provides an opportunity for understanding the mechanism of age‐related compromised fracture healing from the stem cell perspective. In this study, we tested whether hSSCs isolated from geriatric fractures demonstrate intrinsic functional defects that drive impaired healing. Using flow cytometry, we analyzed and isolated hSSCs from callus tissue of five different skeletal sites (n = 61) of patients ranging from 13 to 94 years of age for functional and molecular studies. We observed that fracture‐activated amplification of hSSC populations was comparable at all ages. However, functional analysis of isolated stem cells revealed that advanced age significantly correlated with reduced osteochondrogenic potential but was not associated with decreased in vitro clonogenicity. hSSCs derived from women displayed an exacerbated functional decline with age relative to those of aged men. Transcriptomic comparisons revealed downregulation of skeletogenic pathways such as WNT and upregulation of senescence‐related pathways in young versus older hSSCs. Strikingly, loss of Sirtuin1 expression played a major role in hSSC dysfunction but re‐activation by trans‐resveratrol or a small molecule compound restored in vitro differentiation potential. These are the first findings that characterize age‐related defects in purified hSSCs from geriatric fractures. Our results provide a foundation for future investigations into the mechanism and reversibility of skeletal stem cell aging in humans.

[1]  P. Giannoudis,et al.  The Analysis of In Vivo Aging in Human Bone Marrow Mesenchymal Stromal Cells Using Colony-Forming Unit-Fibroblast Assay and the CD45lowCD271+ Phenotype , 2019, Stem cells international.

[2]  Wei-xu Li,et al.  Bergenin Activates SIRT1 as a Novel Therapeutic Agent for Osteogenesis of Bone Mesenchymal Stem Cells , 2019, Front. Pharmacol..

[3]  D. Miao,et al.  Sirt1 Promotes Osteogenic Differentiation and Increases Alveolar Bone Mass via Bmi1 Activation in Mice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  Austin J. Ramme,et al.  Age-related inflammation triggers skeletal stem/progenitor cell dysfunction , 2019, Proceedings of the National Academy of Sciences.

[5]  G. Favero,et al.  Resveratrol and SIRT1 Activators for the Treatment of Aging and Age-Related Diseases , 2018, Resveratrol - Adding Life to Years, Not Adding Years to Life.

[6]  Bin Zhou,et al.  Overexpression of Sirt1 in mesenchymal stem cells protects against bone loss in mice by FOXO3a deacetylation and oxidative stress inhibition. , 2018, Metabolism: clinical and experimental.

[7]  P. Dayan,et al.  Early childhood investment impacts social decision-making four decades later , 2018, Nature Communications.

[8]  Rachel E. Brewer,et al.  Identification of the Human Skeletal Stem Cell , 2018, Cell.

[9]  P. Frenette,et al.  Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche , 2018, Nature Medicine.

[10]  C. Colnot,et al.  Periosteum contains skeletal stem cells with high bone regenerative potential controlled by Periostin , 2018, Nature Communications.

[11]  K. Alswat Gender Disparities in Osteoporosis , 2017, Journal of clinical medicine research.

[12]  G. Duda,et al.  The haematoma and its role in bone healing , 2017, Journal of Experimental Orthopaedics.

[13]  I. Weissman,et al.  Pharmacological rescue of diabetic skeletal stem cell niches , 2017, Science Translational Medicine.

[14]  R. Jenq,et al.  Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury , 2018, Nature Medicine.

[15]  I. Weissman,et al.  Identification and characterization of an injury-induced skeletal progenitor , 2015, Proceedings of the National Academy of Sciences.

[16]  D. Sahoo,et al.  Identification and Specification of the Mouse Skeletal Stem Cell , 2015, Cell.

[17]  J. Caeiro,et al.  Complications of hip fractures: A review. , 2014, World journal of orthopedics.

[18]  R. Tuan,et al.  Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells , 2014, Stem cells.

[19]  S. M. Friedman,et al.  Epidemiology of fragility fractures. , 2014, Clinics in geriatric medicine.

[20]  R. Atit,et al.  Distinct Requirements for Cranial Ectoderm and Mesenchyme-Derived Wnts in Specification and Differentiation of Osteoblast and Dermal Progenitors , 2014, PLoS genetics.

[21]  I. Bruns,et al.  PDGFRα and CD51 mark human Nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion , 2013, The Journal of experimental medicine.

[22]  N. Ashwood,et al.  Factors influencing fracture healing , 2013 .

[23]  Debashis Sahoo,et al.  Gene Expression Commons: An Open Platform for Absolute Gene Expression Profiling , 2012, PloS one.

[24]  Oddom Demontiero,et al.  Aging and bone loss: new insights for the clinician , 2012, Therapeutic advances in musculoskeletal disease.

[25]  Debashis Sahoo,et al.  Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age , 2011, Proceedings of the National Academy of Sciences.

[26]  L. E. O’Brien,et al.  Altered Modes of Stem Cell Division Drive Adaptive Intestinal Growth , 2011, Cell.

[27]  M. Yen,et al.  Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  G. Duda,et al.  Human Early Fracture Hematoma Is Characterized by Inflammation and Hypoxia , 2011, Clinical orthopaedics and related research.

[29]  J. Caetano-Lopes,et al.  Upregulation of Inflammatory Genes and Downregulation of Sclerostin Gene Expression Are Key Elements in the Early Phase of Fragility Fracture Healing , 2011, PloS one.

[30]  Stephen L Kates,et al.  The 1-Year Mortality of Patients Treated in a Hip Fracture Program for Elders , 2010, Geriatric orthopaedic surgery & rehabilitation.

[31]  M. Morrisey,et al.  The Societal Burden of Osteoporosis , 2010, Current rheumatology reports.

[32]  H. Fujioka,et al.  Human hypertrophic nonunion tissue contains mesenchymal progenitor cells with multilineage capacity in vitro , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[33]  M. Biffoni,et al.  Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. , 2008, Experimental hematology.

[34]  Joel S Greenberger,et al.  Age‐related intrinsic changes in human bone‐marrow‐derived mesenchymal stem cells and their differentiation to osteoblasts , 2008, Aging cell.

[35]  B. Sacchetti,et al.  Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment , 2007, Cell.

[36]  M. Parker,et al.  Incidence of Fracture-healing Complications after Femoral Neck Fractures , 2007, Clinical orthopaedics and related research.

[37]  T. Einhorn The Science of Fracture Healing , 2005, Journal of orthopaedic trauma.

[38]  Xizhi Guo,et al.  Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. , 2005, Developmental cell.

[39]  R. Sanderman,et al.  Gender differences in recovery from injuries to the extremities in older persons. A prospective study , 2003, Disability and rehabilitation.

[40]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[41]  C. Cooper,et al.  Epidemiology of fractures in England and Wales. , 2001, Bone.

[42]  E. Seeman,et al.  Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. , 2001, The Journal of clinical endocrinology and metabolism.

[43]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.